Centre Hospitalier Valence — Clinical Trial Site

42 Registered trials

15 Currently recruiting

Organisation

Centre Hospitalier Valence

Location

Valence, France

Identifier

ORG-100042394

Address

179 Boulevard Marechal Juin, 26000, France

Departments

Département de dermatologie
dermatologie
Dermatology Department
gastro enterology
Gastro-Entérologie
Gastroentérologie
gastroenterology
Gastroenterology department
Head and neck surgery
Hématologie
hématologie et oncologie médicale
Hematology
Hepato Gastro-Entérologie
Hépato-Gastro-Entérologie
Hepato-gastroenterology
hepatogastroenterology
Maladies infectieuses
Medical oncology
Neurology
Onco-Hematology
ONCOLOGIE
oncology
Service d' Hépato-Gastro-Entérologie
Service d'hématologie
Service d'hématologie oncologie
Service d'oncologie médicale
Service de dermatologie
Service de Pneumologie
Service de Réanimation
Service Neurologie

Clinical trials at this site (42)

Search interface

Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled tr… Pending

2024-514633-38-00 Crohn’s Disease 5
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial Pending

2024-514964-24-00 ulcerative colitis 5
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, doub… Pending

2024-515663-59-00 intracerebral haemorrhage 5
Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin (… Pending

2025-520995-24-00 Adult patients treated for haematological disorders, in 5
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt… Pending

2025-521199-80-00 Patients with previously untreated symptomatic chronic 4
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial Pending

2025-524976-40-00 patients with influenza-induced acute hypoxemic respira 5
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis Recruiting

2025-523726-40-00 Multiple Sclerosis 5 2026-06-24
Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR] Recruiting

2025-522193-37-00 Septic arthritis 5 2026-06-09
PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting

2025-522108-26-00 métastatique colorectal cancer 4 2026-02-19
Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting

2024-519971-25-00 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer 5 2025-12-03
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Advanced Biliary Cancer (ABC) 5 2024-06-24
Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi… Recruiting

2023-508154-25-00 Crohn's disease 6 2024-05-27
Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV… Recruiting

2023-506232-32-00 Multiple recurrences of Clostridioides difficile infect 9 2024-04-08
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 9 2022-05-18
Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i… Recruiting

2023-504166-37-00 Advanced ovarian, tubal or peritoneal cancer. 4 2022-02-01
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26